Loading...
Market
Will TERN-601 advance to Phase 2 clinical trials by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Terns Pharmaceuticals official announcements, clinical trial registries
Story
Terns Pharmaceuticals Stock Soars 10% After Positive Phase 1 Trial Results Showing 5.5% Weight Loss
Sep 9, 2024, 11:09 AM
Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for its once-daily oral GLP-1R agonist, TERN-601, aimed at treating obesity. The trial demonstrated a statistically significant mean weight loss of up to 5.5% over 28 days, with a 4.9% placebo-adjusted weight loss. The study also reported the absence of treatment-related dose interruptions, reductions, or discontinuations, with mostly mild adverse events, despite aggressive titration to high doses. Following this announcement, Terns Pharmaceuticals' stock soared by 10%.
View original story
Similar markets
Yes • 50%
No • 50%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Yes • 50%
No • 50%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Yes • 50%
No • 50%
